Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study

Cancers

Francescamaria Donati¹  Carla Cappelli¹  Piero Boraschi¹  Andrea Cacciato Insilla²  Daniela Campani²  Alfredo Falcone³  Caterina Vivaldi³  Emanuele Kauffmann⁴  Niccolò Napoli⁴  Ugo Boggi⁴  Davide Caramella⁵  Silvia Catanese⁶  Valentina Massa⁶  Enrico Vasile⁶  Lorenzo Fornaro⁶  Francesca Salani⁶  Giulia Pasquini⁶  Irene Pecora⁶  Monica Lencioni⁶ 

[1] Department of Diagnostic Imaging, Pisa University Hospital, Via Paradisa 2, 56124 Pisa, Italy;Department of Surgical, Medical, Molecular Pathology and Critical Area, Division of Surgical Pathology, Pisa University Hospital, Via Paradisa 2, 56124 Pisa, Italy;Department of Translational Research and New Surgical and Medical Technologies, University of Pisa, Via Savi 6, 56126 Pisa, Italy;Department of Transplant and General Surgery, Pisa University Hospital, Via Paradisa 2, 56124 Pisa, Italy;Diagnostic and Interventional Radiology, University of Pisa, Via Paradisa 2, 56124 Pisa, Italy;Division of Medical Oncology, Pisa University Hospital, Via Roma 67, 56126 Pisa, Italy;

关键词: early tumor shrinkage;    depth of response;    pancreatic cancer;    FOLFOXIRI;    gemcitabine plus nab-paclitaxel;   

DOI  :  10.3390/cancers11070939

来源: DOAJ

【 摘 要 】

Early tumor shrinkage (ETS) and depth of response (DoR) predict favorable outcomes in metastatic colorectal cancer. We aim to evaluate their prognostic role in metastatic pancreatic cancer (PC) patients treated with first-line modified-FOLFIRINOX (FOLFOXIRI) or Gemcitabine + Nab-paclitaxel (GemNab). Hence, 138 patients were tested for ETS, defined as a ≥20% reduction in the sum of target lesions’ longest diameters (SLD) after 6−8 weeks from baseline, and DoR, i.e., the maximum percentage shrinkage in the SLD from baseline. Association of ETS and DoR with progression-free survival (PFS) and overall survival (OS) was assessed. ETS was reached in 49 patients (39.5% in the FOLFOXIRI, 29.8% in the GemNab group; p = 0.280). In the overall population, ETS was significantly associated with better PFS (8.0 vs. 4.8 months, p < 0.001) and OS (13.2 vs. 9.7 months, p = 0.001). Median DoR was −27.5% (−29.4% with FOLFOXIRI and −21.4% with GemNab, p = 0.016): DoR was significantly associated with better PFS (9.0 vs. 6.7 months, p < 0.001) and OS (14.3 vs. 11.1 months, p = 0.031). Multivariate analysis confirmed both ETS and DoR are independently associated with PFS and OS. In conclusion, our study added evidence on the role of ETS and DoR in the prediction of outcome of PC patients treated with first-line combination chemotherapy.

【 授权许可】

Unknown